changing your setting. We'll assume that you are happy to receive all cookies on the BTG website.
London, UK, 12 April 2013
BTG plc (LSE: BTG), the specialist healthcare company, announces that the New Drug Application (NDA) seeking approval of Varisolve® (polidocanol endovenous microfoam (PEM)) as a comprehensive treatment for varicose veins, which was submitted to the US Food & Drug Administration (FDA) on 4 February 2013, has been accepted for full review by the FDA.
Based on standard review timelines, BTG anticipates potential US approval and launch of PEM during H1 2014.
BTG FTI Consulting
Andy Burrows, Ben Atwell/Simon Conway
Director of Investor Relations +44 (0)20 7831 3113
+44 (0)20 7575 1741;
Mobile: +44 (0)7990 530605
Chief Financial Officer
+44 (0)20 7575 0000
BTG is an international specialist healthcare company that is developing and commercialising products targeting critical care, cancer and other disorders. The company has diversified revenues from sales of its own marketed products and from royalties on partnered products, and is seeking to acquire new programmes and products to develop and market to specialist physicians. For further information about BTG please visit our website at www.btgplc.com.
Select CONTINUE to proceed to the BTG website or LEAVE to learn more at BSC.com